Clinical trials on trial
By Osagie Obasogie,
The New Scientist
| 01. 22. 2011
[Commentary]
A great deal of scientific research – especially in medicine – relies on human subjects. Protecting volunteers has been a prominent social and legal issue since the 1950s, when the world recoiled from the horrors of Nazi medicine.
We have come a long way since then, but it pays to remember that the Nazis did not have a monopoly on atrocities committed in the name of science. One of the worst cases of human subject abuse was perpetrated by American scientists who, between 1932 and 1972, misled hundreds of black people with syphilis in Tuskegee, Alabama, by deliberately leaving them untreated to enable researchers to study the progression of the disease.
To view the entire article, please click below for version in PDF format.
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...